Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas - PubMed (original) (raw)

Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas

Esmeralda Castelblanco et al. Endocr Pathol. 2013 Dec.

Abstract

This is a confirmatory study about usefulness of SDHB and SDHA immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas. Paraganglioma/pheochromocytoma syndrome (PGL/PCC syndrome) consists of different entities, associated with germline mutations in five different genes: SDHD, SDHAF2, SDHC, SDHA and SDHB. It has been suggested that negative immunostaining of SDHB can be taken as an indicator of the presence of a mutation in one of the five SDH genes. We have performed SDHB and SDHA immunohistochemical staining in a series of paragangliomas and pheochromocytomas from 64 patients. The patients had been previously checked for mutations in SDHD, SDHC and SDHB, but also for mutation in RET and VHL. All 14 patients with SDH mutations (9 with SDHB and 5 with SDHD mutations) exhibited negative or weak-diffuse SDHB staining pattern in tumour tissue, whereas cells of the 23 RET mutated and 8 VHL mutated tumours showed a positive SDHB immunostaining. Sixteen of the patients that did not exhibit a mutation in any gene showed positive SDHB immunostaining in tumour tissue, while only three of the patients without mutation exhibited negative staining. All patients exhibited positive pattern of SDHA immunostaining. The results confirm the value of SDHB immunohistochemical status in assessment of germline mutations in PGL/PCC syndrome.

PubMed Disclaimer

Similar articles

• SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
  Menara M, Oudijk L, Badoual C, Bertherat J, Lepoutre-Lussey C, Amar L, Iturrioz X, Sibony M, Zinzindohoué F, de Krijger R, Gimenez-Roqueplo AP, Favier J. Menara M, et al. J Clin Endocrinol Metab. 2015 Feb;100(2):E287-91. doi: 10.1210/jc.2014-1870. Epub 2014 Nov 18. J Clin Endocrinol Metab. 2015. PMID: 25405498
• Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
  Gill AJ, Benn DE, Chou A, Clarkson A, Muljono A, Meyer-Rochow GY, Richardson AL, Sidhu SB, Robinson BG, Clifton-Bligh RJ. Gill AJ, et al. Hum Pathol. 2010 Jun;41(6):805-14. doi: 10.1016/j.humpath.2009.12.005. Epub 2010 Mar 17. Hum Pathol. 2010. PMID: 20236688
• Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline SDHx Gene Mutation.
  Santi R, Rapizzi E, Canu L, Ercolino T, Baroni G, Fucci R, Costa G, Mannelli M, Nesi G. Santi R, et al. Anticancer Res. 2017 Feb;37(2):805-812. doi: 10.21873/anticanres.11381. Anticancer Res. 2017. PMID: 28179334
• Back to Biochemistry: Evaluation for and Prognostic Significance of SDH Mutations in Paragangliomas and Pheochromocytomas.
  Gupta S, Erickson LA. Gupta S, et al. Surg Pathol Clin. 2023 Mar;16(1):119-129. doi: 10.1016/j.path.2022.09.011. Surg Pathol Clin. 2023. PMID: 36739159 Review.
• The Role of Immunohistochemistry and Molecular Analysis of Succinate Dehydrogenase in the Diagnosis of Endocrine and Non-Endocrine Tumors and Related Syndromes.
  Oudijk L, Gaal J, de Krijger RR. Oudijk L, et al. Endocr Pathol. 2019 Mar;30(1):64-73. doi: 10.1007/s12022-018-9555-2. Endocr Pathol. 2019. PMID: 30421319 Review.

Cited by

• SDHA-related phaeochromocytoma and paraganglioma: review and clinical management.
  Kaplan AI, Dwight T, Luxford C, Benn DE, Clifton-Bligh RJ. Kaplan AI, et al. Endocr Relat Cancer. 2024 Sep 21;31(10):e240111. doi: 10.1530/ERC-24-0111. Print 2024 Oct 1. Endocr Relat Cancer. 2024. PMID: 39133175 Free PMC article. Review.
• Immunohistochemical Profiling of SSTR2 and HIF-2α with the Tumor Microenvironment in Pheochromocytoma and Paraganglioma.
  Uchihara M, Tanabe A, Kojima Y, Shimoi T, Maeshima AM, Umamoto K, Shimomura A, Shimizu C, Yamazaki Y, Nakamura E, Matsui Y, Takemura N, Miyazaki H, Sudo K, Yonemori K, Kajio H. Uchihara M, et al. Cancers (Basel). 2024 Jun 11;16(12):2191. doi: 10.3390/cancers16122191. Cancers (Basel). 2024. PMID: 38927897 Free PMC article.
• New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.
  Jhawar S, Arakawa Y, Kumar S, Varghese D, Kim YS, Roper N, Elloumi F, Pommier Y, Pacak K, Del Rivero J. Jhawar S, et al. Cancers (Basel). 2022 Jan 25;14(3):594. doi: 10.3390/cancers14030594. Cancers (Basel). 2022. PMID: 35158861 Free PMC article. Review.
• Pheochromocytoma due to a novel SDHD variant presenting as unilateral visual loss.
  Miller C, Pazderska A, Reynolds J, Gou P, Dunne B, McElhinney K, Owens L. Miller C, et al. Endocrinol Diabetes Metab Case Rep. 2021 Dec 1;2021:21-0107. doi: 10.1530/EDM-21-0107. Online ahead of print. Endocrinol Diabetes Metab Case Rep. 2021. PMID: 34866059 Free PMC article.
• Efficacy of Immunohistochemistry for SDHB in the Screening of Hereditary Pheochromocytoma-Paraganglioma.
  Choi HR, Koo JS, Lee CR, Lee JD, Kang SW, Jo YS, Chung WY. Choi HR, et al. Biology (Basel). 2021 Jul 17;10(7):677. doi: 10.3390/biology10070677. Biology (Basel). 2021. PMID: 34356532 Free PMC article.

References

1. 1. Science. 2000 Feb 4;287(5454):848-51 - PubMed
2. 1. Hum Pathol. 2010 Jun;41(6):805-14 - PubMed
3. 1. N Engl J Med. 2007 Jul 19;357(3):306-8 - PubMed
4. 1. Am J Surg Pathol. 2010 May;34(5):636-44 - PubMed
5. 1. Mol Cell Biol. 2008 Jan;28(2):718-31 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal